JP2013505937A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505937A5
JP2013505937A5 JP2012531012A JP2012531012A JP2013505937A5 JP 2013505937 A5 JP2013505937 A5 JP 2013505937A5 JP 2012531012 A JP2012531012 A JP 2012531012A JP 2012531012 A JP2012531012 A JP 2012531012A JP 2013505937 A5 JP2013505937 A5 JP 2013505937A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012531012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505937A (ja
JP5893561B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/049912 external-priority patent/WO2011038061A2/en
Publication of JP2013505937A publication Critical patent/JP2013505937A/ja
Publication of JP2013505937A5 publication Critical patent/JP2013505937A5/ja
Application granted granted Critical
Publication of JP5893561B2 publication Critical patent/JP5893561B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012531012A 2009-09-25 2010-09-23 新規npr−bアゴニスト Expired - Fee Related JP5893561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
US61/245,960 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015086575A Division JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト

Publications (3)

Publication Number Publication Date
JP2013505937A JP2013505937A (ja) 2013-02-21
JP2013505937A5 true JP2013505937A5 (https=) 2013-09-05
JP5893561B2 JP5893561B2 (ja) 2016-03-23

Family

ID=43781057

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012531012A Expired - Fee Related JP5893561B2 (ja) 2009-09-25 2010-09-23 新規npr−bアゴニスト
JP2015086575A Expired - Fee Related JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015086575A Expired - Fee Related JP6211032B2 (ja) 2009-09-25 2015-04-21 新規npr−bアゴニスト
JP2017101128A Withdrawn JP2017137362A (ja) 2009-09-25 2017-05-22 新規npr−bアゴニスト

Country Status (17)

Country Link
US (5) US8546523B2 (https=)
EP (1) EP2480247B1 (https=)
JP (3) JP5893561B2 (https=)
KR (3) KR20180049198A (https=)
CN (2) CN102548574B (https=)
AR (1) AR078445A1 (https=)
AU (1) AU2010298256B2 (https=)
BR (1) BR112012006579A2 (https=)
CA (1) CA2773949C (https=)
CL (2) CL2012000715A1 (https=)
MX (3) MX354005B (https=)
PH (1) PH12012500562A1 (https=)
RU (3) RU2636738C2 (https=)
TW (2) TWI625126B (https=)
UY (1) UY32902A (https=)
WO (1) WO2011038061A2 (https=)
ZA (3) ZA201201630B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2510942T3 (en) 2005-04-07 2015-12-14 Cardiorentis Ag Use of natriuretic peptides for the treatment of heart failure
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
EP2480247B1 (en) * 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN108653715A (zh) * 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
US20140213520A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3576770A1 (en) 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
ES3034676T3 (en) * 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
IL298980A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
CN1169573C (zh) 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
EP1951277A2 (en) * 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2480247B1 (en) 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Similar Documents

Publication Publication Date Title
JP2013505937A5 (https=)
JP2012525416A5 (https=)
JP2011026329A5 (https=)
JP2012031285A5 (https=)
JP2011006413A5 (https=)
JP2011093937A5 (https=)
JP2013539946A5 (https=)
JP2012524113A5 (https=)
JP2013531034A5 (https=)
JP2012204203A5 (https=)
JP2013531018A5 (https=)
JP2011214087A5 (https=)
JP2014505137A5 (https=)
JP2013064178A5 (https=)
JP2010049241A5 (https=)
JP2012011657A5 (https=)
JP2011208181A5 (https=)
JP2010166925A5 (https=)
JP2012042569A5 (https=)
JP2011207949A5 (https=)
JP2012011658A5 (https=)
JP2012193264A5 (https=)
JP2011146571A5 (https=)
JP2012190699A5 (https=)
JP2013503915A5 (https=)